

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
31 August 2023 (31.08.2023)



(10) International Publication Number
WO 2023/161933 A1

(51) International Patent Classification:

A61K 38/29 (2006.01) *A61K 9/00* (2006.01)
A61K 47/12 (2006.01) *A61P 5/18* (2006.01)
A61K 9/20 (2006.01) *A61P 19/00* (2006.01)
A61K 47/36 (2006.01) *A61P 19/10* (2006.01)
A61K 47/38 (2006.01)

(21) International Application Number:

PCT/IL2023/050191

(22) International Filing Date:

23 February 2023 (23.02.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/313,367 24 February 2022 (24.02.2022) US

(71) Applicant: **ENTERA BIO LTD.** [IL/IL]; Jerusalem Bio Park, Hadassah Ein-Kerem, P.O. Box 12117, 9112002 Jerusalem (IL).

(72) Inventors: **BURSHTEIN, Gregory**; 71/8 Kislev Street, 7177625 Modiin (IL). **ITIN, Constantin**; 24A/4 HaBosem Street, 9076924 Mevaseret-Zion (IL). **GALITZER, Hillel**; 43 Slav Street, 7681200 Yad Binyamin (IL). **SCHWARTZ,**

Phillip M.; 5 David Alro'i Street, Building 1, Apt. 35, 9210806 Jerusalem (IL).

(74) Agent: **EHRlich, Gal** et al.; G.E EHRlich (1995) LTD., Sky Tower, 13th Floor, 35 HaMasger Street, 6721407 Tel Aviv (IL).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) Title: FORMULATIONS COMPRISING ACID-NEUTRALIZING POLYMER FOR ORAL ADMINISTRATION OF PARATHYROID HORMONE

SSG




FIG. 7A

(57) Abstract: A pharmaceutical composition is described herein, which comprises a therapeutically active agent, an absorption enhancer, and a polymer comprising a plurality of alkaline groups. The therapeutically active agent is a parathyroid hormone. A concentration of the polymer in the composition is at least 10 weight percent of the total weight of the composition. The absorption enhancer is preferably a substituted or non-substituted fatty acid or a salt thereof. Further described herein are methods of treating a condition treatable by the therapeutically active agent, comprising orally administering the pharmaceutical composition.

WO 2023/161933 A1

[Continued on next page]

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*